Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 15 04:00PM ET
4.74
Dollar change
-0.04
Percentage change
-0.84
%
Index- P/E- EPS (ttm)-6.47 Insider Own11.05% Shs Outstand47.83M Perf Week-8.85%
Market Cap226.76M Forward P/E- EPS next Y-3.86 Insider Trans-1.00% Shs Float42.55M Perf Month-1.66%
Income-308.48M PEG- EPS next Q-1.28 Inst Own79.15% Short Float5.84% Perf Quarter-23.30%
Sales15.84M P/S14.32 EPS this Y33.53% Inst Trans-4.86% Short Ratio2.39 Perf Half Y-24.88%
Book/sh4.34 P/B1.09 EPS next Y10.27% ROA-40.15% Short Interest2.48M Perf Year-75.72%
Cash/sh12.92 P/C0.37 EPS next 5Y- ROE-90.24% 52W Range4.72 - 22.48 Perf YTD-29.99%
Dividend Est.- P/FCF- EPS past 5Y-22.59% ROI-42.14% 52W High-78.91% Beta0.96
Dividend TTM- Quick Ratio8.68 Sales past 5Y302.35% Gross Margin-61.13% 52W Low0.42% ATR (14)0.27
Dividend Ex-Date- Current Ratio8.85 EPS Y/Y TTM-138.16% Oper. Margin-1388.47% RSI (14)36.41 Volatility4.13% 4.83%
Employees480 Debt/Eq2.56 Sales Y/Y TTM-85.12% Profit Margin-1947.09% Recom1.64 Target Price20.33
Option/ShortYes / Yes LT Debt/Eq2.52 EPS Q/Q-1156.18% Payout- Rel Volume0.65 Prev Close4.78
Sales Surprise19.32% EPS Surprise-4.46% Sales Q/Q-93.49% EarningsFeb 28 BMO Avg Volume1.04M Price4.74
SMA20-8.26% SMA50-13.17% SMA200-33.16% Trades Volume669,156 Change-0.84%
Date Action Analyst Rating Change Price Target Change
Feb-29-24Downgrade Goldman Buy → Neutral $8
Dec-19-23Downgrade Mizuho Buy → Neutral $52 → $10
Mar-17-22Upgrade UBS Neutral → Buy $40
Jun-15-21Initiated BTIG Research Buy $46
May-21-21Initiated UBS Neutral $40
Apr-26-21Resumed Credit Suisse Outperform $78
Apr-01-21Upgrade Mizuho Neutral → Buy $52
Jan-07-21Upgrade Guggenheim Neutral → Buy $62
Nov-24-20Initiated H.C. Wainwright Buy $80
Nov-11-20Initiated Berenberg Buy
Mar-13-24 07:07AM
Feb-29-24 09:06AM
Feb-28-24 08:35AM
08:20AM
07:05AM
03:30AM Loading…
Feb-27-24 03:30AM
Dec-19-23 07:15AM
07:05AM
Dec-11-23 07:30PM
Dec-10-23 11:59AM
Dec-08-23 07:05AM
04:08AM
Nov-29-23 07:05AM
Nov-14-23 10:31PM
Nov-08-23 09:55AM
08:25AM Loading…
Nov-07-23 08:25AM
08:12AM
07:21AM
07:05AM
Oct-30-23 09:32AM
Oct-27-23 10:00AM
Oct-26-23 02:14PM
10:02AM
Oct-25-23 10:02AM
Oct-24-23 07:05AM
Oct-12-23 08:24AM
Oct-06-23 11:31AM
Oct-05-23 01:49PM
08:15AM
07:19AM
07:05AM Loading…
07:05AM
Oct-02-23 07:05AM
Sep-05-23 01:10PM
07:05AM
Sep-01-23 06:51PM
Aug-31-23 10:12PM
Aug-26-23 03:51PM
Aug-06-23 08:05AM
Aug-01-23 09:05AM
07:54AM
07:05AM
Jul-27-23 08:35PM
Jun-28-23 09:20AM
06:02AM
Jun-26-23 07:11AM
Jun-22-23 03:03PM
10:17AM
Jun-21-23 08:00PM
04:08PM
11:46AM
07:05AM
Jun-20-23 07:05AM
07:00AM
Jun-16-23 07:05AM
May-15-23 07:53AM
07:05AM
May-14-23 08:16AM
May-09-23 08:25AM
07:21AM
07:05AM
May-02-23 04:40PM
07:05AM
Apr-26-23 08:00PM
Apr-17-23 10:31AM
Mar-13-23 07:05AM
Mar-10-23 09:07AM
Mar-02-23 07:05AM
Feb-28-23 04:19PM
Feb-27-23 08:25AM
07:05AM
Feb-23-23 08:05AM
08:00AM
05:34AM
Feb-21-23 07:05AM
Jan-31-23 07:05AM
Jan-06-23 05:39AM
Dec-20-22 07:05AM
Dec-16-22 07:15AM
Dec-10-22 10:00AM
Nov-29-22 11:00AM
Nov-23-22 05:30PM
04:14PM
01:19PM
12:39PM
08:12AM
Nov-22-22 04:40PM
03:59PM
Nov-17-22 07:05AM
Nov-10-22 09:55AM
Nov-02-22 08:35AM
07:05AM
Oct-17-22 10:00AM
Oct-11-22 07:05AM
Oct-03-22 07:05AM
Sep-06-22 07:05AM
Aug-14-22 08:23AM
Aug-08-22 11:53AM
11:50AM
08:25AM
07:05AM
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, Managing DirectorFeb 26 '24Sale6.3527,904177,190440,839Feb 28 04:17 PM
KLEMT CHRISTIANChief Financial OfficerFeb 26 '24Sale6.3815,906101,480116,948Feb 28 04:21 PM
CALOZ PIERREChief Operating OfficerFeb 26 '24Sale6.479,45561,17485,643Feb 28 04:33 PM
Dolmetsch RicardoPresident, R&DSep 18 '23Sale7.465,84143,574163,404Sep 20 04:45 PM
CALOZ PIERREChief Operating OfficerJul 10 '23Sale11.3615,117171,72995,098Jul 12 04:49 PM
Gut RobertDirectorJun 16 '23Sale18.883,22860,94547,669Jun 20 05:20 PM
CALOZ PIERREChief Operating OfficerJun 16 '23Sale18.802,92054,896110,215Jun 20 05:14 PM
Soteropoulos PaulaDirectorJun 16 '23Sale18.992,27543,20222,423Jun 20 05:30 PM
Balachandran MadhavanDirectorJun 16 '23Sale18.912,28343,17225,990Jun 20 05:17 PM
Jacques Rachelle SuzanneDirectorJun 16 '23Sale18.762,30143,16716,629Jun 20 05:33 PM
Meek David D.DirectorJun 16 '23Sale18.852,29043,16622,481Jun 20 05:25 PM
Kaye JackDirectorJun 16 '23Sale18.932,28043,16034,119Jun 20 05:23 PM
Springhorn Jeremy P.DirectorJun 16 '23Sale18.882,28643,16025,987Jun 20 05:06 PM
POST LEONARD EDirectorJun 16 '23Sale18.832,29143,14018,221Jun 20 05:28 PM
KLEMT CHRISTIANChief Financial OfficerJun 16 '23Sale18.941,58730,058132,854Jun 20 05:11 PM